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Edited by Gianni CesareniAbstract The mechanism that regulates the plasticity of bone
marrow cells (BMCs) into hepatocytes is poorly understood. We
developed a green ﬂuorescent protein/carbon tetrachloride model
to ﬁnd that BMC transplantation recovered liver damage. Serum
albumin level and liver ﬁbrosis were recovered by BMC
transplantation. To understand the mechanism, we used DNA-
chip technology to proﬁle the change of transient gene expression
before and after BMC transplantation. On the basis of gene
expression with self-organizing map using speciﬁc equation,
genes were classiﬁed into 153 clusters. The information is useful
to understand the dramatic gene activation during the process of
the plasticity of BMC.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Recently, several groups have reported the possible plas-
ticity of bone marrow cells (BMC) to diﬀerentiate into a
variety of non-hematopoietic cell lineages [1,2]. Ever since,
the diﬀerentiation of BMC into hepatocytes in human was
documented following a bone marrow transplantation from a
man to a woman [3]. The mechanism of the plasticity of
BMC was discussed whether that was occurred with cell
fusion, nuclear reprogramming [4–6] or trans-diﬀerentiation
[7,8]. We think both cell fusion and trans-diﬀerentiation
might be important to understand the mechanism of BMC
plasticity. On the other hand, in cardiovascular medicine,
clinical research has been conducted to evaluate the use of
BMCs in regenerating the myocardium and vessels, and some
positive results have been obtained [9,10]. These ﬁndings
suggest the usefulness of BMCs as the source of cells in
developing the next-generation of treatment for liver regen-
eration [11]. We ﬁrst tried to understand how we could use
BMC to repair damaged liver. We have developed a model
[named as a green ﬂuorescent protein/carbon tetrachloride
(GFP/CC14)] to evaluate the usefulness of BMC transplan-
tation for damaged liver [12,13]. In this model, 0.5 ml/kg of
carbon tetrachloride (CCl4) is administered twice weekly to
induce liver cirrhosis and then GFP-positive BMCs are
transplanted through the causal vein [14]. Under continuous
liver injury, immunostaining using anti-GFP antibodies [15]
showed that GFP-positive BMCs migrated into the marginal
area of the hepatic lobule starting from day 1 after BMC
transplantation, and with time, while forming a hepatic cord
towards the central vein, the distribution of GFP-positive
BMCs expands [12,16]. Also, using Liv2, a hepatoblast-spe-
ciﬁc antibody that we developed [17], it has been shown that
BMCs ﬁrst trans-diﬀerentiate into Liv2-positive hepatoblasts
and then diﬀerentiated into albumin-positive hepatocytes.
Furthermore, the level of serum albumin signiﬁcantly in-
creases with time in recipient mice. Liver ﬁbrosis induced by
CCl4 injection was recovered by BMC transplantation [18].
These ﬁndings suggest that this GFP/CCl4 model can be usedation of European Biochemical Societies.
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sistent liver damage condition. It is important to understand
what had happened in GFP/CCl4 model after BMC trans-
plantation in mRNA level. DNA chips are recently devel-
oped tools used in genetic analyses [19]. While it is possible
to obtain genetic data using DNA chips, the vast amount of
information collected makes it diﬃcult to precisely interpret
the factors involved in the gene expression. Therefore, in the
present study, patterns of global gene expression at diﬀerentFig. 1. Deﬁned equation in this analysis. ð#Þ Arrow indicates CCl4 injection t
time point (2 days, 1 week, 2 weeks, 3 weeks, and 4 weeks). yiðtÞ showed the ge
the gene expression level of the liver CCl4 alone injection group. We deﬁne fið
change of gene expression by BMC transplantation. We are interested in f
increase in t.
Table 1
Lists of primers for selected 13 genes
Cluster Gene name (Accession No.) Primer – forward (50–
Primer – reverse (50–3
86 c-kit (NM02099) TCCAACGATGTGGGCA
AATGAGCAGCGGCGTG
86 FGP6 (M92415) CATGGTCTATACCGGC
GGCTGCTGACATGAAA
125 MMP2 (NM008610) CCCTGATGTCCAGCAA
ATTCCAGGAGTCTGCG
125 MMP9 (NM013599) ACGACATAGACGGCAT
TCGGCTGTGGTTCAGT
92 TIMP2 (NM011594) ACACGCTTAGCATCAC
TGTGACCCAGTCCATC
13 HGF (NM010427) CCCAAACATCCGAGTT
TTCCCATTGCCACGAT
1 NumbL (NM010950) TATGCAGCCTCCGTTT
GCGTTGGCTACCATCT
1 HOXD3 (NM010468) CCATAAATCAGCCGCA
GGATGGGTCGAGGACT
152 GPI (NM008155) TGGACGGCAAAGATGT
CGATGTTGATGATGTC
152 VEGF (NM009505) ATGCGGATCAAACCTC
CCGCTCTGAACAAGGC
136 TNFR1 (NM011609) CTGCTCTACGAATCAC
ACAGCATACAGAATCG
151 HNF4 (NM008261) CCAAGTACATCCCGGC
CTAGGAGCAGCACGTC
151 FGF2 (NM008006) GGCTGCTGGCTTCTAA
ACTGCCCAGTTCGTTTtimes were compared between mice with BMC transplanta-
tion and those without. Self-organizing map (SOM) is a
statistical technique that has been recently used in analyzing
microarray data and, via this method, it is possible to visu-
alize a vast amount of complicated and multidimensional
data [20]. In this analysis, we made a speciﬁc equation to
extract genes with expressions that altered in relation to
BMC transplantation. Here, we present the results obtained
from this study.wice a week in GFP/CCl4 model. We analyzed gene expression in each
ne expression level of the liver after BMC transplantation. xiðtÞ showed
tÞ: fiðtÞ ¼ log10 yiðtÞ=xiðtÞ. By using this, we succeeded in extracting the
ollowing the change of the values of FiðtÞ ¼ fiðt þ 1Þ  fiðtÞ with the
30) Target Tm
0)
AGAG 90 55
AA
CACA 88 63
CCAAAG
GTAGATG 148 62
ATGAG
CCAGTA 90 53
TGTG
CCAGA 137 63
CAGAG
GGCTAC 84 63
AACA
GTG 102 62
GTGAA
AGGA 112 63
TACCTTAG
GATG 129 63
CGTGA
ACCA 129 63
TCAC
TCTGCTC 113 62
CAAGGTC
CTTC 132 62
CTTAAAC
GTGTG 129 62
CAGTG
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2.1. Experimental protocol (GFP/CCl4 model)
We developed a new in vivo model in which we could monitor the
plasticity of BMCs into hepatocytes [12,16]. The mouse line C57BL6/
Tg14 (act-EGFP) OsbY01 was a kind gift from Dr. Masaru Okabe
(Genome Research Center, Osaka University, Osaka, Japan) [14].
C57BL/6 female mice were purchased from Japan SLC (Shizuoka,
Japan). We injected 0.5 ml/kg body weight of CCl4 into C57BL/6 mice
at 6 weeks of age via the peritoneum twice a week for 4 weeks to induce
persistent liver damage. At this time, the condition of recipient mice
was liver cirrhosis. One day after 4 weeks of CCl4 injection, 1 105
GFP-positive BMCs were injected slowly using a 31 G needle and
Hamilton syringe via the tail vein. The mice that were injected with
CCl4 only were used as the control group. After BMC transplantation,
the same dose of CCl4 was injected twice a week. Individual mice were
killed at 18 h after initial CCl4 injection (2 days after BMC trans-
plantation) and once a week after BMC transplantation for 4 weeks.
All processes including surgical steps conﬁrmed to the guidance of
Yamaguchi University for animal and recombinant DNA experiments.1
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1072.2. RNA preparation and microarray analysis
In both the BMC transplantation and control groups, the liver
was excised 2 days and 1, 2, 3, and 4 weeks after transplantation.
The mice were killed by cervical dislocation. The whole liver was
removed and immediately frozen in liquid nitrogen. Liver samples
were pooled at least two from whole liver of both mice groups
(BMC transplantation and control CCl4 damage at each points).
Total RNA was isolated from pooled liver samples using an Atlas
Glass Total RNA Isolation Kit (Clontech, Palo Alto, CA) [21].
Single strands of cDNA were synthesized using the primer mix,
dNTP, aminoacryl dUTP, and MMLV-RT using an Atlas Glass
Fluorescent Labeling Kit (Clontech). The synthesized cDNA probes
were coupled to monoreactive Cy3 for ﬂuorescent labeling. Probes
were prepared in the same manner for the control group (no BMC
transplantation) and BMC transplantaion group at the same time.
The DNA microarray analysis was conducted using an Atlas Glass
Mouse 1.0K Microarray System (Clontech) [22]. The above-men-
tioned cDNA probes were hybridized to a DNA chip composed of
about 1100 DNA fragments by incubating the chip overnight at 50
C with the probe. After incubation, the chip was washed using
GlassHyb Wash Solution, RNase water and 20· SSC, rinsed with
distilled water and then air dried. The signal intensity of each gene
was measured using a ﬂuorescent scanner (Axon Instruments, CA).
The spot intensity of expression of each gene was assessed using the
ArrayGauge System (Fuji Film, Tokyo, Japan). The raw data of the
spot intesity were used for SOM analysis (All raw data of micro-
array are available at http://liver-project.med.yamaguchi-u.ac.jp/re-
search/). We performed several analyses to obtain representative
data.11
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Fig. 2. The 1018 genes analyzed using microarray were divided into
153 clusters and arranged in a 17  9 matrix (height  width) of 153
hexagons (all raw data of microarray are available at http://liver-pro-
ject.med.yamaguchi-u.ac.jp/research/). The number of genes varied
among the clusters. Clusters with similar elements were arranged close
to each other in the matrix.2.3. SOM analysis for microarray
The microarray analysis showed that, of the 1100 genes on the DNA
chips, although the expression of some genes was too small for further
analysis, the expression data recorded of the remaining 1018 genes
were suﬃcient for SOM data analysis. At each of ﬁve sampling times,
i.e., 2 days and each week for 4 weeks, expression levels of 1018 genes
for both control CCl4 damage and BMC transplantation group were
measured, respectively. To extract the genes that are diﬀerentially ex-
pressed before and after BMC transplantation, we deﬁned the fol-
lowing equation (Fig. 1):
fiðtÞ ¼ log10
yiðtÞ
xiðtÞ ; t ¼ 1; 2; 3; 4; 5; i ¼ 1; 2; . . . ; 1018 ð1Þ
where xiðtÞ is the expression level of the control CCl4 alone sample
(CCl4 alone without BMC transplantation) and yiðtÞ is the expression
level of BMC transplantation sample for gene i (1,2, . . ., 1018) at
sampling point t, respectively. The term fiðtÞ represents the expression
level of GFP/CCl4 group normalized by the control group. If
yiðtÞ ¼ xiðtÞ, at that the value of fiðtÞ, i.e., log10 1, was zero. By using
this, we succeeded in extracting the change of gene expression by BMC
transplantation. Point t shows time. t ¼ 2d, 1w, 2w, 3w, and 4w
showed 1, 2, 3, 4, and 5, respectively. To extract the change of gene
expression with time, we followed the change of the values offiðt þ 1Þ  fiðtÞ with the increase in t. Using fiðtÞ, we deﬁned the 4-
dimensional vector Fi ¼ ½Fið1Þ; Fið2Þ; Fið3Þ; Fið4ÞT for gene i, where
Fið1Þ ¼ fið2Þ  fið1Þ
Fið2Þ ¼ fið3Þ  fið2Þ
Fið3Þ ¼ fið4Þ  fið3Þ
Fið4Þ ¼ fið5Þ  fið4Þ
All genes were described and then used as input patterns for SOM
analysis. SOM was performed using the SOM toolbox in MATLAB
(The Mathworks Inc., Natick, MA; and http://www.cis.hut.ﬁ/projects/
somtoolbox/).
Each element of these vectors [Fi (i ¼ 1,2,3, . . ., 1018)] represents a
chronological change of gene expression after BMC transplantation in
GFP/CCl4 model.
2.4. Reverse transcriptase (RT)-PCR analysis
Total RNA was isolated from the whole liver of both mice
groups (BMC transplantation and control CCl4 damage (n ¼ 2,
each group) using Isogen Total-RNA isolation kit (Nippon Gene
Co., Ltd., Tokyo, Japan) at each of ﬁve sampling times, i.e., 2 days
and each week for 4 weeks. These samples were obtained by in-
dependent experiments from microarray analysis. RT step was
performed using SYBR RT-PCR kit (Takara Co., Tokyo, Japan).
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20 ll of reaction mixture containing 5 pmol of forward and reverse
primer. PCR was performed for a total of 45 cycles, each of 95 C
for 5 s and 60 C for 20 s [23]. We selected 13 genes to further
clarify the diﬀerence expression pattern of each gene. c-kit, ﬁbro-
blast growth factor (FGF)-6, matrix metalloproteinase (MMP)-2,
MMP-9, tissue inhibitor of metalloproteinase (TIMP)-2, Hepatocyte
growth factor (HGF), Numblike (NumbL) and homeobox (HOX) -
D3, Glucose-6-phosphatase isomerase (GPI), vascular endothelial
growth factor (VEGF), tumor necrosis factor receptor (TNFR)-1,
hepatocyte nuclear factor (HNF)-4 and FGF-2 were selected. The
primer used in this study is shown in Table 1. The relative ratio of
each gene expression was determined referring with the mean ex-
pression level of control house keeping gene, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and 18 S ribosomal RNA
expression.
2.5. SOM analysis compared between RT-PCR and microarray
To validate the results of SOM analysis depend on microarray, we
compared SOM analysis between microarray and RT-PCR. We used
the same equation and performed SOM analysis (Fig. 1) based on both
the data of RT-PCR and microarray.Fig. 3. The median value for gene expression for F1, F2, F3, and F4 in
each cluster is presented as a bar chart. As a reference, in cluster 1, the
median value in F1 and F3 was increased, while that in F2 and F4 was
decreased.3. Results
The 1018 genes that could be analyzed by the DNA chips
were classiﬁed into 153 clusters by SOM (Fig. 2). Genes in the
same cluster showed similar gene expression pattern during the
process of BMC trans-diﬀerentiation. On the SOM matrix,
clusters with similar vector Fi elements (F1–F4) were arranged
in close proximity to each other. Therefore, adjacent clusters
on the matrix exhibited similar chronological changes in gene
expression proﬁles during the process of plasticity of BMC
into hepatocyte. Fig. 3 shows bar charts that represent the
median value of gene expression for each cluster in F1, F2, F3,
and F4. By analyzing each element (F1–F4) of vector Fi, the
clusters were color coded to aid visualization of the SOM data
(Fig. 4). For example, in the F1 output, clusters 69, 70, and 86
containing upregulated genes in F1 were colored dark brown.
On the other hand, clusters with downregulated genes in F1
were colored dark blue. The color bar on the right-hand side of
the ﬁgure indicates the degree of gene expression from F1 to
F4, and a value of 0 indicates that there was little transient
change in gene expression between the BMC transplantation
and control CCl4 injection groups. The following clusters ex-
hibited marked changes in transient gene expression: in F1,
clusters 69, 70, 86, 92, 125, 140, 141, 142, and 143; in F2,
clusters 13, 14, 15, 16, 17, 32, 33, and 34; in F3, clusters 1, 2, 18,
and 137; and in F4, clusters 118, 119, 133, 134, 135, 136, 148,
149, 150, 151, 152, and 153. To validate the data of SOM
analysis based on microarray analysis, we performed SOMFig. 4. The clusters were color-coded based on the median values for
gene expression at the F1, F2, F3, and F4 time periods. The color bar
on the right hand side indicates the values in each period; dark brown
for upregulated and dark blue for downregulated. A value of 0 indi-
cates that there was little chronological change in gene expression
between the transplantation and control groups.
14 K. Omori et al. / FEBS Letters 578 (2004) 10–20analysis based on the data of RT-PCR for selected 13 genes
using the same equation (Figs. 5A and B). Table 2 shows the
list of genes in each cluster.4. Discussion
By using speciﬁc equation to extract change of gene ex-
pression after BMC transplantation, we found that there were
dramatic changes for both gene expression and distribution of
gene clusters after BMC transplantation in GFP/CCl4 model
(Figs. 3 and 4). 1018 genes were classiﬁed into 153 patterns of
change of gene expression using SOM analysis. These results
might show that many genes had important reciprocal roles
during the process of diﬀerentiation of BMC into albumin
positive hepatocyte. To validate the SOM analysis based on
microarray analysis, we performed SOM analysis based on
selected 13 gene expressions analyzed by RT-PCR indepen-
dently. c-kit, FGF6, MMP2, MMP9, and TIMP2 were selected
from serious clusters at F1 periods (clusters 86, 92, and 125).
HGF was selected from F2 periods (cluster 13). NumbL and
HOXD3 were selected from F3 (cluster 1). GPI, VEGF,
TNFR1, HNF4, and FGF2 were selected from F4 (clustersnumbL
HOXD3
c-kit
FGF6
MMP2
MMP9
HNF4
GPI
VEGF
TNFR1
TIMP2
HGF
FGF2
GPI
VEGF
HNF4
FGF6
Microarray analysisA B
Fig. 5. For the genes, the data of microarray (A) and RT-PCR (B) were class
were arranged close to each other in the matrix.136, 151, and 152). As shown in Fig. 5, we found the similar
position of these selected genes. This means that the change of
gene expression from microarray analysis is similar to that
from RT-PCR analysis. These results showed the consistency
of SOM analysis based on microarray using speciﬁc equation.
Cluster with color deeper than dark orange (69, 70, 125, 141,
142, and 143) showed the dramatic change in F1 period
(Fig. 4). The c-kit gene, which was present in cluster 86, en-
codes a stem cell factor receptor which is related with rat he-
patic stem cell, oval cell, activation [24]. FGF-6 was also
extracted in cluster 86. FGF was known to have an important
role of hepatocyte proliferation and liver development [25]. To
focus on the change of F1 to F4 in cluster 86, we found that
genes in cluster 86 were upregulated soon after BMC trans-
plantation suggesting that the expression of these genes
changes dynamically and might have an important role in the
early stage of plasticity of BMC (Fig. 3). In cluster 125, genes
involved in the regulation of liver ﬁbrosis such as MMP2 and
MMP9 were pointed out. These results were consistent with
liver ﬁbrosis recovered by BMC transplantation. MMP9 has
been reported to facilitate the induction of hematopoietic cells
from the marrow via the kit signal transduction pathway [26].
This result might suggest that ECMmight be important for theHGF
c-kit
TNFR1
MMP2
TIMP2
FGF2
MMP9
numbL
HOXD3
RT-PCR analysis
iﬁed into clusters by SOM, respectively. Clusters with similar elements
Table 2
Selected gene grouped to clusters
Cluster No. GenBank ID Gene description
Clusters with remarkable variation of gene expression in F1
86 U52951 Enhancer of zeste homolog 2 (EZH2); ENX1H
X06368 X68932 Macrophage colony-stimulating factor 1 receptor (CSF1R) o-fms proto-oncogone
Y00864 NM02099 c-kit proto-oncogene
U14173 ski proto-oncogene
M92415 Fibroblast growth factor 6 (FGF6)
69 X07439 Homeobox protein 3.1 (HOX3.1)
X57487 Paired box protein 8 (PAX8)
U43788 POU domain class 2-associating factor 1 (POU2AF1); OCT-binding factor 1 (OBF1);
BOB1; OCA-B
M84819 Retinoic acid receptor-c (RXR-c; RXRG)
AF015848 E2F transcription factor 3 (E2F3)
Z22649 mpl proto-oncogene; thrombopoietin receptor
L27105 MOESIN-ezin-radin-like protein (MERLIN); schwannomin (SCH); neuroﬁbromatosis
2(NF2)
U51196 EB1 APC-binding protein
Y00671 met proto-oncogene
Z12604 Matrix metalloproteinase 11 (MMP11); stromelysin 3 (STMY3)
70 D90156 Myogenin (MYOG); myoD1-related protein
U51037 CCCTC-binding factor (CTCF)
U06119 Cathepsin H
142 J04946 Angiotensin-converting enzyme (ACE); dipeptidyl carboxypeptidase I (DCP1);
kinase II
U10551 Gem induced immediate early protein
L34290 Transducin b-5 subunit GTP-binding protein G(i)/G(s)/G(t) b subunit 3
M96653 Adenylate cyctase 6
Z71173 Inositol 1,4,5-triphosphate receptor 2
L76946 Phosphodiesterase 1C
U12919 Adenylate cyclase type VII (AIP pyrophosphate-lyase) (adenylyl cyclase) (KTAA0037)
D31788 BP3 alloantigen
AA000715 S100 calcium-binding protein A1; S-100 protein a chain
U97327 Calcylin binding protein
U73004 Antileukoproteinase 1 (ALP1); secretory leukocyte protease inhibitor
140 U58992 Mothers against decapentaplegic homolog 1 (MADH1; mSMAD1);
TGF-b signaling protein 1
U36203 snoN: ski-related oncogene
D17571 NADPH-cytochromc P450 reductase (CPR); POR
U68058 Secreted frizzled-related protein 3 (SFRP3; mFIZ); frezzled
U77638 Mothers against dpp homolog 5 (SMAD5; MADH5)
M33385 Neurotrophic tyrosine kinase receptor type 2 (NTRK); tyrosine kinase receptor B
(TRKB)
X57277 ras-related C3 botulinum substrate 1 (RAC1)
M21531 Calbindin-28K: calbindin 1 (CALB1)
U53142 Nitric oxide synthase 3, endothelial cell
U37775 Tuberin: TSC2 (tuberous sclerosis 2 protein)
J05261 Lysosomal protective protein; cathepsin A; carboxypeptidase C (CPC); MO54
M81591 Membrane metallo endopeptidase
M14222 Cathepsin B (CTSB)
X15475 Peripherin (PRPH)
141 U61969 Wingless-related MMTV integration site l0a protein (WNT10A)
X76292 Desert hedgehog homolog (DHH); HHG3
X67962 Interleukin 7 (IL7)
X66196 Recoverin (RCV1; RCVRN); cancer-associated retinopathy protein (CAR protein), 23-
kDa photoreoeptor cell-speciﬁc protein
U57311 14-3-3 protein g; protein kinase C inhibitor protein 1 (KCIP1); tyrosine 3-monoox-
ygenase/tryptophan 5-monooxygenase activation protein g polypeptide (YWHAH)
X16490 Macrophage plasminogen activator inhibitor 2 (PAI2; PLANH2)
X05211 Laminin c 1 subunit (LAMC1); laminin B2 subunit
125 U03421 Interleukin 11 (IL11)
M84324 Matrix metalloproteinase 2 (MMP2)
NM008610
X72795 Matrix metalloproteinase 9 (MMP9)
NM013599
M59470 Cystatin C; cystatin 3 (CST3)
(continued on next page)
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Table 2 (continued)
Cluster No. GenBank ID Gene description
143 U94350 Radical fringe homolog (RFNG)
U37720 Cell division cycle 42 homolog (CDC42); 25-kDa GTP-binding protein (G25K)
X73985 Calbindin 2 (CALB2); calretinin
X61432 Calmodulin (CALM; CAM)
U48853 ork-associated substrate (CRKAS; CAS)
U24680 Dishevelled 2 homolog (DVL2)
D00611 Basic immunoglobulin superfamily (BASIGIN; BSG); membrane glycoprotein 42
(GP42), neurothelin; CD147 antigen
M28730 Tubulin b 4 (TUBB4)
Z21848 DNA polymerase d catalytic subunit (POLD1)
92 U37331 T-box protein 6 (TBX6)
M61909 relA proto-oncogene; NF-j-B transcription factor p65 subunit (NF-jB p65)
U18542 Calcitonin receptor 1b
U17985 Cannabinoid receptor 1 (CNR1; CBR), brain cannabinoid receptor
U41285 Segment polarity protein dishevelled homolog 3 (DVL3), DSH homolog 3
X62622 Tissue inhibitor of metalloproteinase 2 (TIMP2)
NM011594
L07803 Thrombospondin 2 (THBS2; TSP2)
X53929 Decorin (DCN); bone proteoglycan II (PG-S2), PG40
X6I435 Neuronal kinesin heavy chain (NKHC); KIF5C
D10061 DNA topoisomerase I (TopI)
D28492 Caspase 2 (CASP2); NEDD2 protein; ICH1 cysteine protease
X66323 X-ray repair-complementing defective repair in Chinese hamster cells 5 (XRCO5)
Clusters with remarkable variation of gene expression in F2
17 AF017085 BAP-135 homolog; DIWSIT; general transcription factor II-l (GTF2I)
U77969 Neuronal PAS domain protein 2
X97817 Semaphorin F(SEMAF)
M84487 Vascular cell adhesion molecule 1 (VCAM1)
M59378 Tumor necrosis factor receptor superfamily member 1B2 (TNFRSF1B2); tumor
necrosis factor receptor 2 (TNFR2)
U25995 Receptor (TNFRSF)-interacting serine-threonine protein kinase 1 (RIPK1; RIP)
L22472 BCL2-associated X protein membrane isoform alpha (BAX-alpha)
L33406 Uromodulin
AF007268 Fibroblast growth factor 15 (FGF15)
AF030433 Dickkopf homolog 1 (mDKK1)
AF031896 Cerberus-related protein1 (CERR1)
X58995 Calcium/calmodulin-dependent protein kinase IV catalytic subunit (CAM kinase-CR;
CAMKIV;
34 D32132 Hairy and enhancer of split protein 5 (HES5)
Z93947 Semaphorin H (SEMAH)
U69535 Semaphorin J (SEMAJ)
X97818 Semaphorin G (SEMAG); SEMA5B
U25416 Tumor necrosis factor receptor superfamily member 8 (TNFRSF8); CD30L receptor
U39643 fas-associated factor 1 (FAF1)
Z22703 Fibroblast growth factor 7 (FGF7)
X63615 Calcium/calmodulin-dependent protein kinase type II b subunit (CAM-kinase II b;
CAMK-II b)
U43187 Mitogen-activated protein kinase kinase kinase 3 (MAPKKK3; MAP3K3; MAPK/
ERK kinase kinase 3 (MEK kinase 3; MEKK3)
L35236 Mitogen-activated protein kinase 10 (MAP kinase 10 MAPK10; PRKM10); MAP
kinase p49 3F12; Stress-activated o-jun N-terminal kinase 3 (JNK3); SAPK/ERK
kinase 2 (SERK2)
U03856 Receptor-type protein tyrosine phosphatase (PTPRCAP); C polypeptide-associated
protein; CD45-Associated protein (C045-AP), LSM
16 L20331 Adenosine A3 receptor
L41145 Bone morphogenetic protein 5 (BMP5)
AB006787 Mitogen-activated protein kinase kinase kinase 5 (MAPKKK5; MAP3K5); MAPK/
ERK kinase kinase S (MEKK5); apoptosis signar-regulating kinase 1 (ASK1)
U92456 Serine/aninine-rich protein speciﬁc kinase 2 (SRPK2), WW domain binding protein 6
(WBP6)
15 X81579 Insulin-like growth factor-binding protein 1 (1GF-binding protein 1; K3FBP1)
U60530 Mothers against decapentaplegic homolog 2 (MADH2; mSMAD2)
AB005141 Klotho protein (KL)
U77039 Four and a half LM domains 1 (FLH1); KyoT
51 Z32675 Hairless protein (HR)
L10075 DNA-binding protein SMBP2
S56660 Retinoic acid receptor b (RAR-b; RARB); nuclear receptor subfamily 1 group B
member 2
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Cluster No. GenBank ID Gene description
X57413 Transforming growth factor b 2 (TQF-beta 2; TOFB2)
M20473 cAMP-dependent protein kinase type I b regulatory chain (PRKAR1B)
Y00703 Guanine nuclaotide-binding protein alpha stimulating activity potypeptide (GNAS)
32 Y07836 Stimulated by retinoic acid protein 14 (STRA14); STRA13; E47 interaction protein 1
(EIP1)
X85993 Collapsin 1; semaphorin IIIA (SEMA3A), SEMAD
L28177 Growth arrest and DNA damage-inducible protein (GADD45), DNA damage-
inducible transcript 1
L33768 Janus tyrosine-protein kinase 3 (JAK3)
U07617 Growth factor receptor-bound protein 2 (GRB2); ASH protein
L02526 Mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1; MAPKK1; MAP2K1;
PRKMK1); MAPK/ERK kinase 1 (MEK1)
U66058 DNA ligase III; polydeoxyribonucleotide synthase (ATP) (DNL3)
L28819 Involucrin (IVL)
33 X97052 Mitogen-activated protein kinase kinase 6 (MAP kinase kinase 6: MAPKK6; MAP2K6;
PRKMK6); MAPK/ERK kinase 6 (MEK6); SAPKK3
L09562 Protein-tyrosine phosphatase c (R-PTP- c; PTPRG)
Z32767 DNA damage repair & recombination protein 52 homolog (RAD52)
14 X81466 Ephrin type A receptor 7 (eph receptor A7; EPHA7), embryonic brain receptor tyrosine
kinase (EBK); developmental kinase 1 (mDK1)
U37522 Tumor necrosis factor superfamily member 10 (TNFSFK 10); TNF-related apoptosis
inducing ligand
D38258 Fibroblast growth factor 9
X77113 Growth diﬀerentiation factor 9 (GDF9)
X06381 Leukemia inhibitory factor (LIF); cholinergic diﬀerentiation factor
Z22532 Syndecan 1 (SYND1)
M75716 Alpha-1-antitrypsin, 1-2 (AAT2), serine proteinase inhibitor 1-2 (SPI1-2); alpha 1
protease inhibitor 2; alpha-1- antiproteinase
M64292 Anti-protiferative B-cell translocation gene 2 (BTG2); NGF- inducible protein TIS21
L23971 Fragile X mental retardation syndrome 1 homolog (FMR1; FMRP)
13 U95610 NIMA-related protein kinase 2 (NEK2)
U05252 Special AT-rich sequence-binding protein 1 (SATB1)
U70017 Cyclin-D binding Myb-like protein (hDMPI)
AF001287 Neural cell adhesion molecule 2 (NCAM2), olfactory axon cell adhesion molecule
(OCAM)
J04806 Osteopontin (OP); bone sialoprotein 1; minopontin; early T-lymphocyte activation 1
protein (ETA1); secreted phosphosprotein 1 (SPP1), calcium oxalate crystal growth
inhibitor protein
X83930 Cadherin 5 (CDH5); vascular epithelial cadherin (VE-cadherin)
AF003747 Zinc transporter 4 (ZNT4)
M16472 Myelin proteolipid protein (PLP). lipophilin; DM20
XI5830 7B2 neuroendrocrine protein: secretogranin V (SGV; SCG5)
X72307 NM010427 Hepatocyte growth factor (HGF)
D84372 Non-receptor type II protein cyrosome, phosphocyrosome phosphrase
M38700 ATP-dependent DNA helicase II 70-kDa subunit 70-kDa thyroid autoantigen; lupus
Ku autoantigen protein p70 CTC box-binding factor 75-kDa subunit (CTCBF; CTC75)
cluster with remarkable variation of gene expression in F3
1 UB6441 NM010950 numfaiike (numbL; m-nbl)
M33158 CD3 antigen zeta (CD3Z)
X04648 Low-aﬃnity IgG Fc receptor II b (FCGR2B)
D49658 LIM-homeodomain protein L3; LHX8
L12705 Engrailed protein (En-2) homolog
D49474 SRY-box containing gene 17 (SOX17)
X73573 Homeobox protein D3 (HOXD3)
NM010468
U62522 Sp4 zinc ﬁnger transcription factor
U25096 Lung Kruppel like factor (LKLF)
X90329 Lbx 1 transcription factor
X61753 Heat shook factor 1
U53925 Transcription factor C1
U97076 FLICE-like inhibitory protein long form (FLIP-L)
18 M55S12 WT1; Wilms tumor protein; tumor suppressor
M16449 Myeloblastosis prato-oncogene (MYB)
X13945 Lung carcinoma myc-related oncogene 1 (L-myc; mycL1)
M26391 Retinoblastoma-associated protein 1 (RB1); phosphoprotein 105 (PP105)
U65594 Breast cancer type 2 susceptibility protein (BRCA2)
U04807 FMS-like tyrosine kinase 3 ligand (FLT3L)
M34563 T-ceB-speciﬁc surface glycoprotein CD28
(continued on next page)
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Cluster No. GenBank ID Gene description
2 M32240 Peripheral myelin protein 22 (PMP22); CD25 antigen; SR13 myelin protein
M63801 Gap junction alpha 1 protein (GJA1), connexin 43 (CXN43; CX43)
AF013282 T-box protein 15 (TBX15); TBX14; TBX8
U63386 Early development regulator 1 (EDRI); pdyhomeotic 1 homolog (mPHI)
J05154 Lecithin cholesterol acyltransferase (LCAT); phosphatidylcholine sterot acyltransfer-
ase; phospholipid cholesterol acyftransferase
137 M55171 Rhodopsin (RHO), opsin (mOPS)
D50311 Myocyte enhancer factor 2B (MEF2B)
X14943 Contactin 1 (CNTN1); F3 neuronal cell adhesion molecule (F3CAM)
U12570 von Hippel-Lindau syndrome homolog (VHLH)
V00727 fos proto-oncogene
U36799 retinoblastoma- like protein 2 (RSL2); retinoblastoma-relatad protein PRB2/p130
S59388 Erythropoietin receptor (EPOR)
Z31683 activin A receptor type 1B
S53216 Tyrosine-protein kinase ryk; kinase vik; nyk-R
AF039601 TGF-bttta receptor type IB (betaglycan); candidate tumor suppressor gene
X06203 Interleukin 8 (IL6)
Clusters with remarkable variation of gene expression in F4
152 L12140 Groucho gene-related protein (GRG); amino enhancer of split protein (AES)
M98502 Zinc ﬁnger protein 46
S79463 Semaphorin I (SEMAI)
X91144 P-selectin glycoprotein ligand 1 (PSGL1: SELPLG; SELP1)
U04294 Electocardiographic QT syndrome 2 potassium channel subunit
M14220 Glucose-6-phosphate isomerase (GPI)
NM008155
M95200 Vascular endothelial growth factor (VEGF)
NM009505
M30643 Heparin-fainding growth factor 5 (HBGF5); ﬁbroblast growth factor 5 (FGF5)
U51866 U17112 Casein kinase II alpha 1 related sequence 4 (CSNK2A1-RS4)
U67916 Dentin sialophosphoprotein (DSPP)
U49739 Unconventional myosin VI
153 S663B5 CREB-binding protein
X85994 Semaphorin IIIC (SEMA3C); SEMAE
U28724 Postmeiotic segregation increased 2 homolog (PMS2)
135 X12875 Neural cell adhesion molecule LI (N-CAM LI; LtCAM; CAML1)
L24755 Bone morphogenetic protein 1 (BMP1)
X83106 MAX dimerization protein (MAD)
U34960 Transducin beta-2 subunit
D86726 MCM6 DMA replication licensing factor (P105MCM)
136 D31967 Jumonji protein
U59496 Hypoxia inducible factor 1 alpha subunit (HIF1-alpha; HIF1A); ARNT-interactmg
protein
X85992 Somaphorin C (SEMAC)
X07640 Cell surface glycoprotein MAC-1 alpha subunit; CR-3 alpha subunit; GD11B antigen;
leukocyte adhesion receptor MO1; integrin alpha-M (ITGAM)
X57796 Tumor necrosis factor receptor 1 (TNFR1)
NM011609
X53798 Small inducible cytokine subfampy B member 2 (SCYB2); macrophage inﬂamatory
protein 2 (M1P2)
X78850 Mitogen actived kinase-activated protein kinase 2 (MAPKAP kinase 2; MAPKAPK2);
60-kDa ribosomal protein S6 kinase potypeptide 1 (RPS6KC1)
U43144 Phospholipase C b 3 (PLC-b 3; PLCB3)
X83536 Matrix metalloproteinase 14 (MMP14): membrane-type matrix matatoproteinase 1
(MTMMP1)
Y13602 Filensin, beaded ﬁlament structural protein in lens 1 (BFSP1)
150 AF033011 distal-less homeobox protein 5 (DLX5)
D63644 Aryl hydrocarbon receptor nuclear translocator 2 (ARNT2)
S70632 S70756
S70629 T-cell leukemia homeobox 1 (TLX1); homeobox protein 11 (HOX11)
S81932 distal-less homeobox protein 3 (DLX3)
X75330 Drosophila NK5 transcription factor-related locus 1 (NKX-5.1), H6 homeobox protein
3 (HMX3)
U89487 U89489 LIM homeobox protein cofactor 1A (CUM1A); CUM1B; LIM domain-binding protein
3 (LDB3)
U36340 CACCC-box-binding protein basic Kruppel like factor (BKLF): Kruppel-like factor 3
(KLF3)
U42554 Single-minded 2 (SIM2)
U33626 Promyelocytic leukemia gene (PML)
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X56135 Prothymosin alpha (PTMA)
U43512 Dystroglycan 1
M13071 A-raf proto-oncogene
M36829 Heat shock 84-kDa protein 1 (HSP84-1); HSP90
M89802 Wingless-related MMTV integration site 7b protein (WNT7B)
M30903 B-lymphocyte kinase (BLX)
U43298 Laminin b 3 subunit (LAMB3); kalinin B1 subunit
151 D29015 Hepatic nuclear factor 4-alpha (HNF4-alpha)
NM008281
M31042 Immediate early response protein 2 (IER2); T-lymphocyte activated protein; cyclo-
heximide-induced Protein 1 (CHX1)
U43900 STAM; signal transducing adaptor molecule
M13177 Transforming growth factor b 1 (TGF-b 1; TGFB1)
M30644 Fibroblast growth factor 2 (FGF2)
NM008006
M76601 Cardiac myosin heavy subunit alpha isoform (MYH6; MYHCA)
148 AB009453 Transcription factor 21 (TCF21); basic helix-loop-helix factor COR1; POD1
S71659 LIM homeobox protein 4 (LHX4); GSH4
S79041 Genomic screened homeobox protein 2 (GSH2)
U58533 est2 repressor factor (ERF)
J03770 Homeobox protein D4 (HOXD4); HOX4.2; HOX5.1
X59252 Homeobox protein 8 (HOX8)
J03168 Interferon regulatory factor 2 (1RF2)
S68108 Brahma-related protein 1 (BRG1); swi/snf-related matrix-associated actin dependent
regulator of chromatin subfamily a member 4 (SMARCA4)
D78382 Transducer of erbB2 (TROB; TOB)
X59421 Fli-1 ets-related proto-oncogene
M62860 Myelin protein zero
D31942 Oncostatin M (OSM)
M29464 Platelet-derived growth factor A subunit (PDGFA; POGF1)
M69042 PKC-d; protein kinase C d type
U29539 Retinoic acid-inducible E3 protein; stimulated by retinoic acid 13 (STRA13),
hematopoetic-speciﬁc Protein E3; orfB
U26967 Cordon-bleu protein (COBL)
149 L38248 LIM homeobox protein 3 (LHX3; UM3)
X56230 Octamer-binding transcription factor 1 (OCT1; OTF1); NF-A1; POU domain class 2
transcription factor 1 (POU2F1)
X13721 Homeobox protein 2.4 (HOX2.4)
L04662 c-Aminobutyric acid transporter 4 (GABA-A transporter 4; GABT4)
U59746 B-cell lymphoma protein W (BCLW); BCL2-like protein 2 (BCL2L2)
M16819 Lymphotoxin alpha (LTA), tumor necrosis factor b (TNF-b; TNFB)
U12147 Laminin alpha 2 subunit (LAMA2). dystrophia muscularis protein (DV); merosin
heavy chain; laminin M subunit
U22421 Leptin (LEP); obese factor (OB)
133 D10329 CD7 antigen
D86603 btb and cnc homolog 1 (BACH1)
U36384 Dermis expressed 1 protein (DERM01)
M58633 P58/GTA; galactosy transferase associated protein kinase (cdc2-related protein kinase)
D83698 Activator of apoptosis harakiri (HRK); neuronal death protein 5 (DP5); BID3
L08235 Clusterin (CLU); clustrin; apolipoprotein J (APOJ); sulfated glycoprotein 2 (SGP2;
mSGP2)
X07414 DNA excision repair protein ERCC1
134 U61155 LIM homeobox protein 2 (LIM2); LHX5
U20553 p57kip2; cdk-inhibitor kip2 (cyclin-dependent kinase inhibitor 1 B); member of the
p21CP1 Cdk inhibitor family; candidate tumor suppressor gene
U05671 Adenosine At receptor (ADORA1)
L37663 Acetylcholine receptor alpha 7 neural
M97017 Bone morphogenetic protein 8A (BMP8A), ostoogenic protein 2 (OPS)
AF027503 guanylate kinase membrane-associated inverted protein 1 (GUKMI1; MAGI-1)
M84817 Retinoid X receptor alpha (RXR-aJpha; RXRA)
J03520 Tissue plasminogen activator (T-plasminogon activator PLAT; TPA)
118 X99063 Zyxin(ZYX)
X14194 Nidogen (NID); entactin (ENT)
119 Y15001 Iroquois-related homeobox protein 3 (IRX3)
Z23066 Microphthalmia-associated transcription factor (MITF; MI); microphthaltmia-related
protein
X73360 Transducin-like enhancer of split protein 3 (TLE3; ESG)
(continued on next page)
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Cluster No. GenBank ID Gene description
U65091 Melanocyte-speoiﬁc gene 1 (MSG1); Cbp/p300-interacting transactivator with Glu/Asp-
rich carboxy-terminal domain 1 (CITED1)
X97986 Desmocollin 1A/1B (DSC1)
U81317 Myelin-associated oligodendrocytic basic protein
U21050 TNF receptor-associated factor 3 (TRAF3); TRAFAMN; C040 receptor-associated
factor 1 (CRAF1)
D83966 Protein tyrosine phosphatase
L19622 Tissue inhibitor of metalloproteinase 3 (TIMP3); SUN
AF021031 DiGeorge syndrome chromosome region 6 protein (DGCR6)
20 K. Omori et al. / FEBS Letters 578 (2004) 10–20plasticity of BMC. In the F2 time period, clusters 13, 14, 15,
16, 17, 32, 33, and 51 were dramatically changed. In cluster 13,
hepatocyte growth factor (HGF) was discovered. HGF is in-
volved in hepatocyte proliferation [27,28]. HGF might also
have an important role in GFP/CCl4 model. In the F3 time
period, clusters 1, 2, 18, and 137 were focused. NumbL is in-
volved in asymmetric division of nerve precursor cells [29]. The
HOXD3 genes encode information important for determining
the positional relationships of the antero-posterior axis in
embryogenesis [30]. NumbL and HOXD3 might have an im-
portant role in regulating the plasticity of BMC. In F4, clusters
118, 119, 133, 134, 135, 136, 148, 149, 150, 151, 152, and 153
were found. In this period, genes involved in hepatocyte dif-
ferentiation and homeostasis, such as GPI and HNF4, were
focused [31]. This enzyme is essential for the glycolytic me-
tabolism of hepatocytes. In the GFP/CCl4 model, the level of
albumin in bone marrow-derived hepatocytes increased sig-
niﬁcantly [12]. The fact that an enzyme such as GPI was in-
duced at this period suggests that, at 4 weeks after BMC
transplantation, transplanted BMCs begin to possess some of
the metabolic functions of hepatocytes. HNF4-a was also
upregulated in F4 period. HNF4 plays an important role in the
metabolic regulation of hepatocytes [32,33]. These results
might be related with BMC diﬀerentiated into functional he-
patocyte at this period in GFP/CCl4 model. VEGF was also
upregulated. VEGF promotes vasculogenesis and liver regen-
eration [34]. VEGF might also have an important role in ac-
celerating the liver regeneration in GFP/CCl4 model. Gene
involved in inﬂammation such as TNF-R1 was also pointed
out in GFP/CCl4 model. TNF-alpha related inﬂammation
signal is important in the generation of hepatoblast [17]. These
results also showed that TNF-a related signal might be im-
portant for plasticity of BMC in GFP/CCl4 model.
Here, we analyzed the change of molecular signature after
BMC transplantation in GFP/CCl4 model in mRNA level. Still
many precise things are unconﬁrmed, but we think the infor-
mation is useful to understand the mechanism of the plasticity
of BMC in GFP/CCl4 model. In the future, we are planning to
further analyze the mechanisms.
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